Compare HDL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDL | COLL |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | Singapore | United States |
| Employees | 13651 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.4M | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | HDL | COLL |
|---|---|---|
| Price | $14.98 | $31.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.17 |
| AVG Volume (30 Days) | 848.0 | ★ 538.0K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $10.47 | $5.93 |
| Revenue Next Year | $14.04 | N/A |
| P/E Ratio | $55.56 | ★ $18.73 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $14.51 | $23.23 |
| 52 Week High | $23.62 | $50.79 |
| Indicator | HDL | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 38.25 | 23.00 |
| Support Level | N/A | $31.01 |
| Resistance Level | $17.71 | $32.92 |
| Average True Range (ATR) | 0.21 | 1.31 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 23.66 | 0.29 |
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.